Poor prognosis in young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio: a population-based prospective cohort study

Author(s):  
Yunus Çolak ◽  
Shoaib Afzal ◽  
Børge G. Nordestgaard ◽  
Jørgen Vestbo ◽  
Peter Lange
2018 ◽  
Vol 51 (3) ◽  
pp. 1702681 ◽  
Author(s):  
Yunus Çolak ◽  
Shoaib Afzal ◽  
Børge G. Nordestgaard ◽  
Jørgen Vestbo ◽  
Peter Lange

A presumed consequence of using a fixed ratio for the definition of airflow limitation (AFL) has been overdiagnosis among older individuals and underdiagnosis among younger individuals. However, the prognosis of younger individuals with potentially underdiagnosed AFL is poorly described. We hypothesised that potential underdiagnosis of AFL at a younger age is associated with poor prognosis.We assigned 95 288 participants aged 20–100 years from the Copenhagen General Population Study into the following groups: individuals without AFL with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ≥0.70 and ≥lower limit of normal (LLN) (n=78 779, 83%); individuals with potentially underdiagnosed AFL with FEV1/FVC ≥0.70 and <LLN (n=1056, 1%); individuals with potentially overdiagnosed AFL with FEV1/FVC <0.70 and ≥LLN (n=3088, 3%); and individuals with AFL with FEV1/FVC <0.70 and <LLN (n=12 365, 13%). We assessed risk of exacerbations, pneumonias, ischaemic heart disease, heart failure and all-cause mortality. Median follow-up was 6.0 years (range: 2 days–11 years).Compared to individuals without AFL, individuals with potentially underdiagnosed AFL had an increased risk of morbidity and mortality with age- and sex-adjusted hazard ratios (HR) of 2.7 (95% CI: 1.7–4.5) for pneumonias, 2.3 (95% CI: 1.2–4.5) for heart failure, and 3.1 (95% CI: 2.1–4.6) for all-cause mortality.Young and middle-aged adults with AFL according to LLN but not fixed ratio experience increased respiratory and cardiovascular morbidity and early death.


2021 ◽  
Vol 10 (6) ◽  
pp. 2164-2174
Author(s):  
An‐Ran Liu ◽  
Qiang‐Sheng He ◽  
Wen‐Hui Wu ◽  
Jian‐Liang Du ◽  
Zi‐Chong Kuo ◽  
...  

2021 ◽  
pp. 1-37
Author(s):  
Melanie L. Hill ◽  
Brandon Nichter ◽  
Peter J. Na ◽  
Sonya B. Norman ◽  
Leslie A. Morland ◽  
...  

2020 ◽  
Vol 29 (10) ◽  
pp. 1993-2001
Author(s):  
Kimberly D. van der Willik ◽  
Mohsen Ghanbari ◽  
Lana Fani ◽  
Annette Compter ◽  
Rikje Ruiter ◽  
...  

Diabetologia ◽  
2021 ◽  
Author(s):  
Ziyi Zhou ◽  
John Macpherson ◽  
Stuart R. Gray ◽  
Jason M. R. Gill ◽  
Paul Welsh ◽  
...  

Abstract Aims/hypothesis People with obesity and a normal metabolic profile are sometimes referred to as having ‘metabolically healthy obesity’ (MHO). However, whether this group of individuals are actually ‘healthy’ is uncertain. This study aims to examine the associations of MHO with a wide range of obesity-related outcomes. Methods This is a population-based prospective cohort study of 381,363 UK Biobank participants with a median follow-up of 11.2 years. MHO was defined as having a BMI ≥ 30 kg/m2 and at least four of the six metabolically healthy criteria. Outcomes included incident diabetes and incident and fatal atherosclerotic CVD (ASCVD), heart failure (HF) and respiratory diseases. Results Compared with people who were not obese at baseline, those with MHO had higher incident HF (HR 1.60; 95% CI 1.45, 1.75) and respiratory disease (HR 1.20; 95% CI 1.16, 1.25) rates, but not higher ASCVD. The associations of MHO were generally weaker for fatal outcomes and only significant for all-cause (HR 1.12; 95% CI 1.04, 1.21) and HF mortality rates (HR 1.44; 95% CI 1.09, 1.89). However, when compared with people who were metabolically healthy without obesity, participants with MHO had higher rates of incident diabetes (HR 4.32; 95% CI 3.83, 4.89), ASCVD (HR 1.18; 95% CI 1.10, 1.27), HF (HR 1.76; 95% CI 1.61, 1.92), respiratory diseases (HR 1.28; 95% CI 1.24, 1.33) and all-cause mortality (HR 1.22; 95% CI 1.14, 1.31). The results with a 5 year landmark analysis were similar. Conclusions/interpretation Weight management should be recommended to all people with obesity, irrespective of their metabolic status, to lower risk of diabetes, ASCVD, HF and respiratory diseases. The term ‘MHO’ should be avoided as it is misleading and different strategies for risk stratification should be explored. Graphical abstract


Sign in / Sign up

Export Citation Format

Share Document